← Leaderboards
Luigi Grasso
Navrogen, Inc.
$184,000
Attributed
$184,000
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $115K · FY2020–25$200K$150K$100K$50K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$184,000 · 2
By mechanism
R03$184,000 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Names”
- John Damon Chodera · Sloan-Kettering Inst Can Research$24,538,508
- John E West · University Of Texas At Austin$16,850,000
- Timothy M Willson · University Of Cape Town$12,760,250
- Robert Frenck · Cincinnati Childrens Hosp Med Ctr$11,901,917
- Sonia Savelli · University Of Washington$11,147,222
- Anna Upton · Global Alliance For Tb Drug Development$10,496,979
Research focus
NamesRituximabFc ReceptorMediatingProgression-Free SurvivalsResistanceClinically RelevantComplement-Dependent CytotoxicityImmunosuppressionLibrariesProductionAnti-Cd20AntibodiesProteinsCa-125 AntigenCellsBindingAntibody-Dependent Cell CytotoxicityFundingFutureIn VivoLeadNext GenerationScreening
Grant awards (2)
Characterization of HIO-2, a tumor-produced protein that inhibits therapeutic antibody-mediated cellular cytotoxicity via Fc Receptor (CD16a) blockade$115,000
R03 · FY2025 · CA · contact PI
Next-generation anti-CD20 rituximab antibody that is engineered to be resistant to the immuno-suppressive effect mediated by the tumor-shed antigen, CA125$69,000
R03 · FY2020 · CA · contact PI